Koyfin Home > Directory > Health Care > Revance Therapeutics > EBITDA Margin

Revance Therapeutics EBITDA Margin Chart (RVNC)

Revance Therapeutics annual/quarterly EBITDA Margin from 2012 to 2020. An EBITDA margin is a measurement of a company's earnings before interest, taxes, depreciation, and amortization as a percentage of its total revenue.
  • Revance Therapeutics EBITDA Margin for the quarter ending June 06, 2020 was $-18,626m a -387.93% increase of 72,257m year over year
  • Revance Therapeutics EBITDA Margin for the last 12 months ending June 06, 2020 was $-41,287m a 53.99% decrease of -22,290m year over year
  • Revance Therapeutics Annual EBITDA Margin for 2019 was $-39,116m a 90.34% decrease of -35,338m from 2018
  • Revance Therapeutics Annual EBITDA Margin for 2018 was $-3,779m a -1,071.98% increase of 40,507m from 2017
  • Revance Therapeutics Annual EBITDA Margin for 2017 was $-44,286m a 41.51% decrease of -18,382m from 2016
Other Margins & Efficiency Metrics:
  • Revance Therapeutics Return on Capital % for the quarter ending September 09, 2018 was -42.91 a 7.87% decrease of -3.38 year over year
  • Revance Therapeutics Return on Equity % for the quarter ending September 09, 2018 was -67.02 a -4.32% increase of 2.89 year over year
View Chart On Koyfin

Quarterly RVNC EBITDA Margin Data

06/2020$-18,626m
03/2020$-103,829m
12/2019$-51,026m
09/2019$-90,883m
03/2019$-12,949m
12/2018$-7,788m
09/2018$-1,405m
06/2018$-5,029m
03/2018$-18,276m
12/2017$-87,789m

Annual RVNC EBITDA Margin Data

2019$-39,116m
2018$-3,779m
2017$-44,286m
2016$-25,904m
2015$-23,441m
2014$-13,055m
2013$-5,890m
2012$-5,775m
2011$-4,624m